Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update

Slide: 35 of 40

Conclusions (1 of 2)

  • The ability of medications to decrease fracture risk is most strongly established for postmenopausal women with osteoporosis (i.e., bone density scores in the osteoporosis range and/or pre-existing fractures).
  • Bisphosphonates, denosumab, raloxifene, and teriparatide reduce vertebral fracture risk, but only alendronate, risedronate, zoledronic acid, and denosumab reduce hip fracture risk.
  • Raloxifene does not reduce the risk of hip or nonvertebral fractures.
  • Limited evidence supports a potential benefit for vitamin D and calcium (alone or in combination) in lowering fracture risk.
  • Studies to date are inadequate to provide estimates of the benefits or harms of exercise.